Seattle Genetics has been claimed to be the best oncology research company in the world. It is located in Washington DC and it has a great scientific and business standing in the world. Seattle Genetics has been in the forefront in the fight against cancer. The company has over 800 employees who are qualified in the field of cancer research. The members of the company have a passion for caring for cancer patients. They seek to improve the quality of care that cancer patients receive. The company is aware of the discomfort that cancer patients go through and the emotional distress that the family members go through. The main focus of the company is to fill the gaps in the area of cancer research.
The company has many innovations that seek to develop new and improved techniques in the treatment of cancer. The company is also developing new range of products that will be instrumental in the treatment of cancer. The company has impacted the lives of millions of people around the world. It has been said to have revolutionized the treatment of cancer. The technologies developed by the company have dignified the treatment of cancer and have eased the suffering of cancer patients around the world.
The most talked about innovation by the company is the Antibody-based Conjugates. This technology is an alternative to chemotherapy treatment. It seeks to target only the affected cancer cells unlike chemotherapy treatment which is indiscriminative with regards to cancer cells and the good cells. Seattle Genetics focused on this aspect in the treatment of cancer because studies showed that many of the cancer patients do not survive the vigorous chemotherapy treatment. The chemotherapy treatment is brutal to the human body.
Behind every successful company is a great leader. In this case, the leader is Dr. Clay Siegall. He is the co-founder of Seattle Genetics, its Chief Executive Officer and the Chairman of the Board. Under his leadership, Seattle Genetics has managed to come up with ground breaking innovations in the treatment of cancer and it has also had great financial success. The company is one of the few oncology research companies that is publicly listed.